Cara Therapeutics Inc  

(Public, NASDAQ:CARA)   Watch this stock  
Find more results for CARA
14.20
-0.35 (-2.41%)
Real-time:   12:28PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.00 - 14.63
52 week 4.26 - 17.20
Open 14.59
Vol / Avg. 474,822.00/1.92M
Mkt cap 383.46M
P/E     -
Div/yield     -
EPS -1.64
Shares 27.28M
Beta 3.28
Inst. own 53%
Mar 8, 2017
Q4 2016 Cara Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -649.22%
Operating margin - -662.32%
EBITD margin - -640.26%
Return on average assets -53.77% -29.60%
Return on average equity -59.97% -31.51%
Employees 20 -
CDP Score - -

Address

4 Stamford Plz
STAMFORD, CT 06902-3834
United States - Map
+1-203-4063700 (Phone)
+1-203-5671510 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Officers and directors

Derek T. Chalmers Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Josef C. Schoell CPA Chief Financial Officer
Age: 65
Bio & Compensation  - Reuters
Frederique Menzaghi Ph.D. Vice President, Research & Development
Age: 48
Bio & Compensation  - Reuters
Joseph William Stauffer Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Harrison M. Bains Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters
Jeffrey L. Ives Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Dean Slagel Independent Director
Age: 46
Bio & Compensation  - Reuters
Martin A. Vogelbaum Independent Director
Age: 50
Bio & Compensation  - Reuters